Nutex Health Inc

For the period ended Dec 31, 2023. Filed Mar 29, 2024.

About this filing

A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.

FY2023 · Filed Mar 29, 2024

NUTX$186.25-4.1%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

Item 8. Consolidated Statements of Cash Flows


· · Year ended December 31,
	2023		2022		2021
Cash flows from operating activities:
Net income (loss)		$(43,423,715)		$(432,739,618)		$168,525,285
Adjustment to reconcile net income (loss) to net cash from operating activities:
Depreciation and amortization		17,591,572		13,131,374		7,662,464
Debt accretion expense		1,209,981		1,952,829		50,273
Impairment of assets		29,082,203		-		-
Impairment of goodwill		1,139,297		398,135,038		-
Stock-based compensation expense		2,835,971		189,581		-
Rescission of warrant exercise expense		-		561,651		-
Other income - gain on PPP loan forgiveness		-		-		(5,546,597)
Deferred tax expense (benefit)		(5,707,323)		4,996,209		-
(Gain) loss on lease termination		58,210		-		(109,494)
Non-cash lease expense		131,582		64,143		97,578
Changes in operating assets and liabilities:
Accounts receivable		(969,761)		56,622,133		(5,392,614)
Accounts receivable - related party		(3,613,885)		1,454,934		(1,229,940)
Inventories		142,701		(719,107)		(1,088,489)
Prepaid expenses and other current assets		(817,297)		(1,419,139)		(233,114)
Accounts payable		(4,715,101)		10,018,100		6,365,978
Accounts payable - related party		2,466,536		(329,155)		(97,985)
Accrued expenses and other current liabilities		5,845,481		(1,311,865)		4,429,141
Net cash from operating activities		1,256,452		50,607,108		173,432,486

Cash flows from investing activities:
Acquisitions of property and equipment		(9,496,832)		(14,632,414)		(36,926,591)
Acquired cash in reverse acquisition with Clinigence		-		12,716,228		-
Payments for acquisitions of businesses, net of cash acquired		(703,893)		-		-
Cash related to deconsolidation of Real Estate Entities		(1,039,157)		(2,421,212)		(48,853)
Net cash from investing activities		(11,239,882)		(4,337,398)		(36,975,444)

Cash flows from financing activities:
Proceeds from lines of credit		2,340,911		2,623,479		-
Proceeds from notes payable		16,952,905		815,881		19,614,372
Proceeds from convertible notes		4,909,864		-		-
Repayments of lines of credit		(1,592,714)		(72,055)		(864,659)
Repayments of notes payable		(16,479,512)		(7,237,094)		(20,715,235)
Repayments of finance leases		(3,484,683)		(1,721,224)		(1,255,486)
Payment of debt issuance costs		-		-		(47,875)
Rescission of warrant exercise		-		(588,042)		-
Common stock issued for exercise of warrants		-		4,119,141		-
Common stock issued for exercise of options		-		644,974		-
Members' contributions		298,032		4,513,867		21,753,773
Members' distributions		(5,214,581)		(51,231,657)		(144,337,923)
Net cash from financing activities		(2,269,778)		(48,132,730)		(125,853,033)
Net change in cash and cash equivalents		(12,253,208)		(1,863,020)		10,604,009
Cash and cash equivalents - beginning of the year		34,255,264		36,118,284		25,514,275
Cash and cash equivalents - end of the year		$22,002,056		$34,255,264		$36,118,284

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.